Edition:
United Kingdom

Sorrento Therapeutics Inc (SRNE.OQ)

SRNE.OQ on NASDAQ Stock Exchange Capital Market

2.45USD
2:58pm GMT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.45
Open
$2.45
Day's High
$2.50
Day's Low
$2.40
Volume
50,984
Avg. Vol
164,878
52-wk High
$6.05
52-wk Low
$1.50

Latest Key Developments (Source: Significant Developments)

Sorrento Therapeutics Enteres Into Securities Purchase Agreement
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Sorrento Therapeutics Inc ::SORRENTO THERAPEUTICS SAYS ON DEC 11, CO ENTERED INTO SECURITIES PURCHASE AGREEMENT - SEC FILING.SORRENTO THERAPEUTICS SAYS AGREED TO ISSUE, SELL TO PURCHASERS, IN A PRIVATE PLACEMENT, CONVERTIBLE PROMISSORY NOTES IN OF $50 MILLION.  Full Article

Sorrento Therapeutics says co entered into an at market issuance sales agreement with B. Riley FBR as sales agent
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sorrento Therapeutics Inc :Sorrento Therapeutics - ‍On Nov. 9, 2017, co entered into an at market issuance sales agreement with B. Riley FBR, Inc., as sales agent - SEC Filing​.Sorrento Therapeutics Inc - ‍ Pursuant to sales agreement, co may offer and sell through agent up to $100 million in shares of common stock​.  Full Article

Sorrento Therapeutics files for mixed shelf of upto $350 mln
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sorrento Therapeutics Inc :Sorrento Therapeutics Inc files for mixed shelf of upto $350 million - SEC filing‍​.  Full Article

Scintilla Pharma, a unit of Sorrento Therapeutics, to buy Semnur Pharma
Monday, 15 Aug 2016 

Sorrento Therapeutics : Scintilla will pay semnur an initial payment of $60 million, consisting of $40 million in cash and $20 million in shares of sorrento . Scintilla pharmaceuticals,a subsidiary of sorrento therapeutics, inc., to acquire semnur pharmaceuticals .Additional cash consideration of up to $140 million may be paid by scintilla to semnur upon achievement of certain milestones.  Full Article

Scintilla to acquire Scilex Pharmaceuticals
Monday, 8 Aug 2016 

Scintilla Pharmaceuticals Inc: In consideration for deal, Scilex equity holders to receive up to $70 million in stock of Scintilla, after next equity financing of Scintilla . Has entered into a binding term sheet to acquire Scilex Pharmaceuticals, Inc .Acquisition is contingent upon completion of each parties' due diligence and other customary closing conditions.  Full Article

Sorrento Therapeutics to form JV with Cha Biotech to develop and commercialize natural killer cell therapies
Tuesday, 2 Aug 2016 

Sorrento Therapeutics Inc : Jv covers products on a global basis with exception of greater chinese market . To get exclusive license to develop cbt's novel investigator-initiated trial stage akc technology in major territories . Will also gain access to akc technology for use outside jv alone or with any other sorrento products . Sorrento to form joint venture with Cha Biotech to develop and commercialize natural killer cell therapies .Both cbt and sorrento will make contributions of $2 million to jv.  Full Article

Sorrento, Servier enter exclusive worldwide license, collaboration agreement
Monday, 11 Jul 2016 

Sorrento Therapeutics : Sorrento and Servier enter into exclusive worldwide license and collaboration agreement for development and commercialization of anti-PD-1 antibody . Financial terms of agreement include, among other things, a non-refundable upfront payment to Sorrento of EUR 25 million . May also receive development milestone payments for initial product and each additional product . May receive up to EUR 710 million in payments based on commercial sales milestones .To be entitled to receive royalties on sales of commercialized products ranging from high single-digit to double-digit percentages.  Full Article

Sorrento Therapeutics files for stock shelf of up to $176.6 mln - SEC Filing
Wednesday, 29 Jun 2016 

Sorrento Therapeutics Inc :Says files for stock shelf of up to $176.6 million with U.S. SEC - SEC Filing.  Full Article

Henan Yulin Green Engineering reports passive stake in Sorrento Therapeutics
Thursday, 23 Jun 2016 

Sorrento Therapeutics Inc :Henan Yulin Green Engineering Co Ltd reports passive stake of 6.3% Sorrento Therapeutics Inc as of June 7, 2016 - Sec filing.  Full Article

Sorrento, 3Sbio announce CAR-T joint venture in China
Tuesday, 7 Jun 2016 

Sorrento Therapeutics Inc : 3Sbio will make total contributions of $10 million to joint venture . 3Sbio will initially own 51% of joint venture while TNK will initially hold remaining 49%. . tnk will grant JV exclusive license to CEA CAR-T technology and two additional CARS for cellular therapy for greater china market .Sorrento And 3Sbio Announce CAR-T joint venture in China.  Full Article

BRIEF-Sorrento Therapeutics Enteres Into Securities Purchase Agreement

* SORRENTO THERAPEUTICS SAYS ON DEC 11, CO ENTERED INTO SECURITIES PURCHASE AGREEMENT - SEC FILING